Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RIGL vs BCRX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
RIGL Captures Overall Composite Edge (59.9 HOLD vs 42.2 HOLD), While BCRX Leads 4–2 on Growth & Valuation Pillars
RIGL Overall Winner
6-Pillar Tally: RIGL 2 – 4 BCRX
Matrix Metrics: RIGL 6 – 4 BCRX
As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) captures the overall head-to-head institutional edge over BioCryst Pharmaceuticals Inc (BCRX) on higher Unified Composite conviction (59.9/100 HOLD vs. 42.2/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning, R&D & Supply-Chain Moat), while BCRX wins 4–2 across the 6-pillar growth and valuation breakdown. RIGL trades at $43.73 (9.3x Forward P/E, 26.3% operating margin) versus BCRX at $7.53 (8.9x Forward P/E, 48.8% operating margin).
- Growth vs. Quality Trade-Off: RIGL earns the overall head-to-head edge with a stronger Unified Composite Score (59.9/100 HOLD vs. BCRX 42.2/100 HOLD) and 1.05β · 74% Vol risk profile, whereas BCRX leads top-line expansion (+13.1% YoY revenue growth, 9.39x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6); meanwhile BCRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About RIGL vs BCRX
RIGL
Head-to-Head Winner
Rigel Pharmaceuticals Inc. (New)
$43.73
-1.64% 1D
Market Cap
$860.3M
TTM Revenue
$288M
Forward P/E
9.3x
Beta / 30D Vol
1.05β · 74% Vol
Unified Composite Score
59.9
HOLD
Tech 48.0
Fund 58.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
BCRX
BioCryst Pharmaceuticals Inc
$7.53
-1.05% 1D
Market Cap
$1.9B
TTM Revenue
$962M
Forward P/E
8.9x
Beta / 30D Vol
0.77β · 42% Vol
Unified Composite Score
42.2
HOLD
Tech 24.0
Fund 52.0
Flow 67.0
Mom 68.9
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (RIGL 2 – 4 BCRX)
1. Valuation Multiples
BCRX
Forward P/E
9.3x
8.9x
Trailing P/E
2.8x
13.0x
PEG Ratio
N/M
9.39x
EV / Revenue
2.9x
2.7x
2. Growth & Scale
BCRX
Revenue Growth (YoY)
+16.5%
+13.1%
Earnings Growth (YoY)
-55.5%
+133.3%
TTM Revenue (USD)
$288M
$962M
Market Cap
$860.3M
$1.9B
3. Profitability & Quality
BCRX
Gross Margin
70.7%
78.1%
Operating Margin
26.3%
48.8%
Net Profit Margin
106.6%
-37.4%
Return on Equity (ROE)
109.2%
-1925.4%
4. Balance Sheet & Cash Flow
BCRX
Cash Generation (TTM)
$19M
$366M
Cash Flow Margin
6.7%
38.0%
Net Cash / Leverage
$39M Net Cash
$687M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RIGL
Options Structure Phase
CONSOLIDATION
BREAKDOWN
Current IV / %ile
61.2% (4th %ile)
60.0% (12th %ile)
Put/Call OI Skew
N/A
0.24x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
RIGL
OpEx & R&D Intensity
44.4% of Rev ($128M)
29.3% of Rev ($282M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: RIGL (6) vs BCRX (4)| Institutional Metric | RIGL | BCRX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $860.3M | $1.9B | BCRX | |
| Trailing P/E Ratio | 2.8x | 13.0x | RIGL | |
| Forward P/E Ratio | 9.3x | 8.9x | BCRX | |
| Revenue Growth (YoY) | +16.5% | +13.1% | RIGL | |
| Operating Margin (TTM) | 26.3% | 48.8% | BCRX | |
| Net Profit Margin | 106.6% | -37.4% | RIGL | |
| Return on Equity (ROE) | 109.2% | -1925.4% | RIGL | |
| 52-Week Range Position | 68% ($25–$53) | 26% ($6–$11) | RIGL | |
| Beta / 30D Volatility | 1.05β · 74% Vol | 0.77β · 42% Vol | BCRX | |
| Unified Institutional Score | 59.9 / 100 (HOLD) | 42.2 / 100 (HOLD) | RIGL | |
| Trailing 12M Revenue (USD) | $288M | $962M | Scale | |
| Gross Profit Margin (TTM) | 70.7% | 78.1% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 2.9x EV/Rev | 9.39x PEG · 2.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $19M ($39M Net Cash) | $366M ($687M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BCRX +1.53 pp
3M Horizon
RIGL +22.62 pp
6M Horizon
RIGL +68.9 pp
1Y Horizon
RIGL +0.52 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RIGL Revenue | BCRX Revenue | RIGL Op. Margin | BCRX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $40M | $20M | -163.3% | -456.2% | RIGL |
| FY2019 | $60M | $50M | -116.5% | -203.7% | RIGL |
| FY2020 | $110M | $20M | -26.7% | -981.1% | RIGL |
| FY2021 | $150M | $160M | -8.4% | -113.1% | RIGL |
| FY2022 | $120M | $270M | -46.2% | -54.8% | RIGL |
| FY2023 | $120M | $330M | -17.5% | -31.3% | RIGL |
| FY2024 | $180M | $450M | 13.5% | -0.6% | RIGL |
| FY2025 | $290M | $870M | 42.6% | 39.0% | RIGL |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
RIGL
CONSOLIDATION
Current IV
61.2%
IV Percentile
4th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact RIGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BCRX
BREAKDOWN
Current IV
60.0%
IV Percentile
12th %ile
Put/Call OI Skew
0.24x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact BCRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
RIGL Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
44.4% of Rev ($128M)
90D Engineering Disclosures
0 Published
BCRX Moat Profile
High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
29.3% of Rev ($282M)
90D Engineering Disclosures
0 Published
Investor FAQ RIGL vs BCRX Key Questions & Quantitative Answers
As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) captures the overall head-to-head institutional edge over BioCryst Pharmaceuticals Inc (BCRX) on higher Unified Composite conviction (59.9/100 HOLD vs. 42.2/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning, R&D & Supply-Chain Moat), while BCRX wins 4–2 across the 6-pillar growth and valuation breakdown. RIGL trades at $43.73 (9.3x Forward P/E, 26.3% operating margin) versus BCRX at $7.53 (8.9x Forward P/E, 48.8% operating margin). Growth vs. Quality Trade-Off: RIGL earns the overall head-to-head edge with a stronger Unified Composite Score (59.9/100 HOLD vs. BCRX 42.2/100 HOLD) and 1.05β · 74% Vol risk profile, whereas BCRX leads top-line expansion (+13.1% YoY revenue growth, 9.39x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6); meanwhile BCRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BCRX leads the Growth & Scale pillar: RIGL posts +16.5% YoY revenue growth and -55.5% YoY earnings growth on $288M TTM revenue (70.7% gross margin, 26.3% operating margin), compared with BCRX at +13.1% YoY revenue growth and +133.3% YoY earnings growth on $962M TTM revenue (78.1% gross margin, 48.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RIGL cumulative revenue shifted +625.0% while BCRX shifted +4250.0%. In operating R&D and SG&A reinvestment, RIGL deploys 44.4% of Rev ($128M) (0 90-day corporate R&D disclosures) versus 29.3% of Rev ($282M) (0 disclosures) for BCRX.
BCRX screens cheaper on headline valuation multiples. RIGL trades at 9.3x Forward P/E, 2.8x Trailing P/E, N/M PEG, and 2.9x EV/Revenue (6.7% FCF margin), whereas BCRX trades at 8.9x Forward P/E, 13.0x Trailing P/E, 9.39x PEG, and 2.7x EV/Revenue (38.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RIGL (109.2% ROE) versus BCRX (-1925.4% ROE) capital efficiency.
In options market volatility and institutional positioning, RIGL carries 61.2% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.05β · 74% Vol realized risk). By comparison, BCRX carries 60.0% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.77β · 42% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BCRX vs RIGL · Reverse Pair
RIGL vs VSTM
· Sector Peer
RIGL vs VNDA
· Sector Peer
BCRX vs ACAD
· Sector Peer
BCRX vs AGEN
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma